Oncolytics Biotech Inc (ONC) - Total Liabilities
Based on the latest financial reports, Oncolytics Biotech Inc (ONC) has total liabilities worth CA$13.88 Million CAD (≈ $10.04 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Oncolytics Biotech Inc (ONC) cash flow conversion to assess how effectively this company generates cash.
Oncolytics Biotech Inc - Total Liabilities Trend (1999–2024)
This chart illustrates how Oncolytics Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Check ONC asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Oncolytics Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Oncolytics Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cashbil
JSE:CSB
|
South Africa | ZAC5.34 Billion |
|
SKYX Platforms Corp
NASDAQ:SKYX
|
USA | $57.30 Million |
|
Bank Dinar Indonesia Tbk PT
JK:DNAR
|
Indonesia | Rp9.62 Trillion |
|
Excelliance MOS
TWO:5299
|
Taiwan | NT$753.56 Million |
|
Limes Schlosskliniken AG
XETRA:LIK
|
Germany | €20.16 Million |
|
Leifheit Aktiengesellschaft
F:LEI
|
Germany | €97.19 Million |
|
DongKook Pharmaceutical Co. Ltd
KQ:086450
|
Korea | ₩299.16 Billion |
|
PT Satu Visi Putra Tbk
JK:VISI
|
Indonesia | Rp108.31 Billion |
Liability Composition Analysis (1999–2024)
This chart breaks down Oncolytics Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Oncolytics Biotech Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncolytics Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncolytics Biotech Inc (1999–2024)
The table below shows the annual total liabilities of Oncolytics Biotech Inc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$14.20 Million ≈ $10.27 Million |
+26.18% |
| 2023-12-31 | CA$11.26 Million ≈ $8.14 Million |
+3.92% |
| 2022-12-31 | CA$10.83 Million ≈ $7.84 Million |
+10.74% |
| 2021-12-31 | CA$9.78 Million ≈ $7.08 Million |
+1.97% |
| 2020-12-31 | CA$9.59 Million ≈ $6.94 Million |
-51.47% |
| 2019-12-31 | CA$19.77 Million ≈ $14.30 Million |
+127.98% |
| 2018-12-31 | CA$8.67 Million ≈ $6.27 Million |
-12.13% |
| 2017-12-31 | CA$9.87 Million ≈ $7.14 Million |
+142.50% |
| 2016-12-31 | CA$4.07 Million ≈ $2.94 Million |
+50.16% |
| 2015-12-31 | CA$2.71 Million ≈ $1.96 Million |
-19.69% |
| 2014-12-31 | CA$3.37 Million ≈ $2.44 Million |
-43.85% |
| 2013-12-31 | CA$6.01 Million ≈ $4.35 Million |
-17.59% |
| 2012-12-31 | CA$7.29 Million ≈ $5.27 Million |
+12.10% |
| 2011-12-31 | CA$6.50 Million ≈ $4.71 Million |
+160.10% |
| 2010-12-31 | CA$2.50 Million ≈ $1.81 Million |
-43.50% |
| 2009-12-31 | CA$4.43 Million ≈ $3.20 Million |
-2.38% |
| 2008-12-31 | CA$4.53 Million ≈ $3.28 Million |
+60.71% |
| 2007-12-31 | CA$2.82 Million ≈ $2.04 Million |
+1.98% |
| 2006-12-31 | CA$2.77 Million ≈ $2.00 Million |
+50.15% |
| 2005-12-31 | CA$1.84 Million ≈ $1.33 Million |
+67.61% |
| 2004-12-31 | CA$1.10 Million ≈ $795.19K |
+6.22% |
| 2003-12-31 | CA$1.03 Million ≈ $748.65K |
-26.61% |
| 2002-12-31 | CA$1.41 Million ≈ $1.02 Million |
-54.78% |
| 2001-12-31 | CA$3.12 Million ≈ $2.26 Million |
+78.92% |
| 2000-12-31 | CA$1.74 Million ≈ $1.26 Million |
+638.27% |
| 1999-12-31 | CA$236.10K ≈ $170.79K |
-- |
About Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal aden… Read more